Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment’s efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.
FDA unveils new rare disease pilot program to increase agency-sponsor communications
The FDA on Friday unveiled new details around a rare disease pilot program that seeks to increase rapid, ad-hoc communications between six sponsors working on
September 30, 2023